Dyne Therapeutics Shares Rise After Announcing Positive Topline Results for z-rostudirsen in Phase 1/2 DMD Trial [Yahoo! Finance]
Dyne Therapeutics, Inc. (DYN)
Last dyne therapeutics, inc. earnings: 11/1 04:30 pm
Check Earnings Report
US:NYSE Investor Relations:
dynegy.com/investors/presentations-events
Company Research
Source: Yahoo! Finance
topline results from the Registrational Expansion Cohort of its Phase 1/2 DELIVER trial. The trial is evaluating zeleciment rostudirsen (z-rostudirsen, also known as DYNE-251) in individuals with Duchenne muscular dystrophy/DMD amenable to exon 51 skipping. The DELIVER trial also provided new positive long-term clinical data from its ongoing open-label extension and long-term extension portions. Z-rostudirsen is an investigational therapeutic using Dyne's FORCE platform, designed to enable the production of near full-length dystrophin by conjugating a phosphorodiamidate morpholino oligomer to an antigen-binding fragment that binds to the transferrin receptor 1. The drug has received Breakthrough Therapy, Fast Track, and Rare Pediatric Disease designations from the US FDA, as well as Orphan Drug designation from the FDA, EMA, and MHLW in Japan. The REC met its primary endpoint and showed a statistically significant increase in muscle content-adjusted dystrophin expression to 5.46%
Show less
Read more
Impact Snapshot
Event Time:
DYN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DYN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DYN alerts
High impacting Dyne Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
DYN
News
- Dyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional SharesGlobeNewswire
- Dyne Therapeutics (NASDAQ:DYN) had its price target raised by analysts at Stifel Nicolaus from $36.00 to $39.00. They now have a "buy" rating on the stock.MarketBeat
- Dyne Therapeutics: Why The $350M Public Offering Was Critical [Seeking Alpha]Seeking Alpha
- Dyne Therapeutics (NASDAQ:DYN) was upgraded by analysts at Oppenheimer Holdings, Inc. from a "market perform" rating to an "outperform" rating.MarketBeat
- Dyne Therapeutics Announces Pricing of Upsized $350.0 Million Public Offering of Common StockGlobeNewswire
DYN
Earnings
- 5/8/25 - Miss
DYN
Sec Filings
- 12/10/25 - Form 424B5
- 12/10/25 - Form 8-K
- 12/8/25 - Form 424B5
- DYN's page on the SEC website